ObsEva SA (OBSV): Price and Financial Metrics


ObsEva SA (OBSV): $0.17

0.02 (+10.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OBSV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OBSV Stock Price Chart Interactive Chart >

Price chart for OBSV

OBSV Price/Volume Stats

Current price $0.17 52-week high $3.04
Prev. close $0.15 52-week low $0.13
Day low $0.16 Volume 957,800
Day high $0.17 Avg. volume 1,352,085
50-day MA $0.24 Dividend yield N/A
200-day MA $1.27 Market Cap 13.24M

ObsEva SA (OBSV) Company Bio


ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women between the ages of 15 and 49 suffering from reproductive health and pregnancy. The company intends to develop treatments for treating endometriosis, uterine fibroids, and preterm labor. The company was founded in 2012 and is based in Switzerland.


OBSV Latest News Stream


Event/Time News Detail
Loading, please wait...

OBSV Latest Social Stream


Loading social stream, please wait...

View Full OBSV Social Stream

Latest OBSV News From Around the Web

Below are the latest news stories about OBSEVA SA that investors may wish to consider to help them evaluate OBSV as an investment opportunity.

H.C. Wainwright Reaffirms Their Hold Rating on ObsEva SA (OBSV)

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on ObsEva SA (OBSV - Research Report) today. The company's shares closed yesterday at $0.14.According to TipRanks, Selvaraju is an analyst with an average return of -36.1% and a 13.65% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, Aeterna Zentaris, and Enlivex Therapeutics.Currently, the analyst consensus on ObsEva SA is a Hold with an average price target of $1.00.See the top stocks recommended by analysts >>Based on ObsEva SA's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $32.8 million.

Howard Kim on TipRanks | September 28, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!

William White on InvestorPlace | September 16, 2022

After FDA Regulatory Setback, Penny Stock ObsEva Cuts 70% Of Its Staff

After running into a major roadblock at the FDA for its uterine fibroid drug, ObsEva SA (NASDAQ: OBSV) has flagged plans for significant layoffs as part of a wholesale restructuring under the supervision of the supervision court-appointed administrator. In an update, ObsEva plans to lay off approximately 70% of employees, including Katja Buhrer, Chief Strategy Officer. The company intends to complete the terminations in Q4 and shave $7.6 million off its annual expenses. In August, the company sa

Yahoo | September 13, 2022

ObsEva Announces Progress on Restructuring Initiatives

$7.6 million annual savings expected via reduction-in-force currently underway$6.2 million savings expected from assignment of legacy linzagolix program contracts to Kissei Pharmaceutical Co., Ltd., including $1.7 million of accounts payable assigned to date. Additional assignments are expected in the coming weeks.Company submitted plan to regain compliance with Nasdaq’s minimum stockholders’ equity rule. Additionally, Nasdaq provides notice of noncompliance with Nasdaq’s minimum bid price listi

Yahoo | September 13, 2022

This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'

HC Wainwright has downgraded ObsEva SA (NASDAQ: OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified ObsEva of review issues regarding deficiencies in the linzagolix application for uterine fibroids. These review issues preclude discussion of labeling and post-marketing commitments at this time. ObsEva said that the resolution of the identified review issues might not be feasible by the September 13 target action date under the Prescription Drug User Fee Act. Acc

Yahoo | August 30, 2022

Read More 'OBSV' Stories Here

OBSV Price Returns

1-mo N/A
3-mo -90.34%
6-mo -88.19%
1-year -94.35%
3-year -97.70%
5-year -98.04%
YTD -91.46%
2021 -4.33%
2020 -45.55%
2019 -69.83%
2018 29.71%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6246 seconds.